Natural course and outcomes of children with ubiquitin‐specific protease 53 (USP53)‐related genetic chronic cholestasis
Seema Alam,Bikrant Bihari Lal,Aathira Ravindranath,Ashish Bavdekar,Nirmala Dheivamani,Pandey Snehavardhan,Aashay Shah,Parijat Ram Tripathi,Aabha Nagral,K. P. Srikanth,Ira Shah,Somashekara Hosaagrahara Ramakrishna,Arya Suchismita,Yogesh Waikar,Vaibhav Shah,Zahabiya Nalwalla,Karunesh Kumar,Arjun Maria,Anupam Sibal,Viswanathan M. Sivaramakrishnan,Nishant Wadhwa,A. Ashritha,Vikrant Sood,Rajeev Khanna,Indian PFIC Registry
DOI: https://doi.org/10.1002/jpn3.12392
2024-10-25
Journal of Pediatric Gastroenterology and Nutrition
Abstract:Ubiquitin‐specific protease 53 (USP53) is essential for formation of cellular tight junctions and variations in this gene disrupt the tight junctions, resulting in cholestasis. We describe the clinical manifestations and outcomes of patients with USP53 mutations from the Indian progressive familial intrahepatic cholestasis registry. All 29 patients who harbored mutations in the USP53 gene either in the homozygous, compound heterozygous, or heterozygous state and presented with cholestasis were included. USP53 variants related to cholestasis had good outcomes, with native liver survival in 82.7%, whereas 17.3% required liver transplantation. Jaundice developed in 93% and within 3 months of age in 48.8%. Jaundice resolved in 21 (72.4%). Pruritus 76% at a median age of 7 months (severe in 10/22, 45% and refractory to medical therapy in 4, 18.1%). Majority of them (82.7%) had biallelic mutations. Protein‐truncating mutations were present in 20 (69%) and missense mutations in 9 (31%). No correlation was found between the genotype and the outcome.
pediatrics,gastroenterology & hepatology,nutrition & dietetics